Evidence map›Paper›PMID 28294492›Full record

ArticleHIV medicine2017

High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs.

M E Socías, L Ti, H Dong, J Shoveller, T Kerr, J Montaner, M-J Milloy

Open access · bronzeAbstract read
In one paragraph

Article in HIV medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Hepatitis C Virus Infection and Hospital-Related Outcomes: A Systematic Review.Canadian journal of gastroenterology & hepatology · 2024
    Pooled it
  2. Pooled it
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

M E SocíasBritish Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada.
L TiBritish Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada.
H DongBritish Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada.
J ShovellerBritish Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada.
T KerrBritish Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada.
J MontanerBritish Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada.
M-J MilloyBritish Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada.
St. Paul's Hospital · CAUniversity of British Columbia · CA

Funding

Impacts of universal access to HIV/AIDS care among HIV+ injection drug usersR01DA021525 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI MILLOY, M-J · 2007 to 2016
$5.8M
Impacts of universal access to HIV/AIDS care among HIV+ injection drug usersU01DA021525 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI MILLOY, M-J · 2017 to 2024
$4.3M
Mentoring the next generation of addiction clinician scientists while responding to the opioid epidemicR25DA037756 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI FAIRBAIRN, NADIA · 2014 to 2023
$3.6M
Seek and Treat for Optimal Prevention of HIV & AIDS (STOP HIV/AIDS) in BCR01DA036307 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI MONTANER, JULIO SERGIO GONZALEZ · 2013 to 2017
$3.0M
NIDA NIH HHS R01 DA021525NIDA NIH HHS R01 DA036307NIDA NIH HHS R25 DA037756NIDA NIH HHS U01 DA021525
6 · The paper itself

Abstract

objectivesDespite the high burden of hepatitis C virus (HCV)-related morbidity and mortality among HIV-positive people who use illicit drugs (PWUD), uptake of interferon-based treatments for HCV infection has been negligible among this group. Direct-acting antiviral (DAA) therapies offer an opportunity to expand treatment access among this population. The aim of this study was to explore willingness to use DAA-based regimens among HIV/HCV-coinfected PWUD in Vancouver, Canada.

methodsData were drawn from the AIDS Care Cohort to evaluate Exposure to Survival Services (ACCESS), a prospective cohort of HIV-positive PWUD. Using logistic regression analyses, we investigated factors associated with willingness to use DAA-based regimens among HIV/HCV-coinfected participants.

resultsOf 418 HIV/HCV-coinfected PWUD surveyed between June 2014 and May 2015, 295 (71%) were willing to use DAA-based regimens. In multivariable analysis, participants enrolled in methadone maintenance therapy [adjusted odds ratio (AOR) 1.61; 95% confidence interval (CI) 1.04-2.51], those with a recent assessment by an HCV specialist (AOR 2.02; 95% CI 1.28-3.19) and those who perceived that HCV infection was affecting their health (AOR 2.49; 95% CI 1.41-4.37) were more likely to be willing to use DAA-based regimens.

conclusionsOverall, this study found a high prevalence of willingness to use DAA-based regimens among HIV/HCV-coinfected PWUD in Vancouver. Importantly, enrolment in methadone maintenance therapy was positively associated with willingness, suggesting that integrated models of HIV, HCV and addiction care should be explored as a way to address HCV-related morbidity and mortality among HIV/HCV-coinfected PWUD.

Indexed as

AdultAntiviral AgentsCanadaCoinfectionFemaleHepatitis CHIV InfectionsHumansMalePatient CompliancePrevalenceProspective StudiesSubstance-Related DisordersTreatment OutcomeAntiviral Agentsdirect-acting antiviral agentshepatitis CHIVmethadone maintenance therapypeople who use drugs

Identifiers

PMID28294492
PMCPMC5819997
OpenAlexW2602557977

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.